

Quotes Thesis

1. Chronic hyponatremia is not benign, affected patients have a reduced quality of life and suffer from neurocognitive and neuromuscular disorders (*this thesis*).
2. The sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin is a new treatment option for patients with chronic hyponatremia caused by the syndrome of inadequate antidiuresis (SIAD) (*this thesis*).
3. Patients with low somatostatin subtype 2 (SST₂) expressing neuroendocrine tumors have worse outcome than patients with high SST₂ expressing neuroendocrine tumors (*this thesis*).
4. DNA methylation plays a role in the regulation of SST₂ expression in small intestinal neuroendocrine tumors (*this thesis*).
5. To date, epigenetic treatment with DNA methyltransferase inhibitors has not resulted in clinically significant upregulation of SST₂ expression in patients with neuroendocrine tumors (*this thesis*).
6. To improve patient safety, central diabetes insipidus needs to be renamed to arginine vasopressin (AVP) deficiency (*Arima H. et al, Eur J Endocrinol. 2022 14;187(5):P1-P3*).
7. Given the ambiguous definition of malignancy, non-metastatic insulinomas should be referred to as "indolent" and metastatic insulinomas as "aggressive" to better reflect their biological behavior (*Hackeng WM et al, Endocr. Rel. Cancer 2023 27;30(5):e220321*).
8. DNA-methylation based machine learning algorithms have the potential to outperform conventional histological-immunohistochemical tumor diagnostics in terms of precise entity-specific diagnostic classification and determination of predictive markers (*Hench J, Swiss Med Forum. 2020;20(0910):150-154*).
9. The escalating obesity crisis is fueled in part by increased consumption of ultra-processed foods, underscoring the urgency of a transition to a slow food culture as a critical solution to promoting healthier eating habits and tackling obesity.

10. Climate-related events, including natural disasters, extreme weather conditions, and environmental changes, will result in a higher prevalence of patients experiencing stress-induced dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis.

11. "Why not?" is a slogan for an interesting life (*Mason Cooley*).